WO2025163615 - HIGH LEVEL PRODUCTION OF GLP1 ANALOGUES
National phase entry is expected:
Publication Number
WO/2025/163615
Publication Date
07.08.2025
International Application No.
PCT/IB2025/051159
International Filing Date
03.02.2025
Title **
[English]
HIGH LEVEL PRODUCTION OF GLP1 ANALOGUES
[French]
PRODUCTION À HAUT NIVEAU D'ANALOGUES DE GLP1
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LTD.
Inventors
MODY, Rustom
BOSE, Sandip
KARNWAL, Vaibhav
GUPTA, Shivika
ROY, Ajoy
THENNATI, Rajamannar
NATARAJAN, Muthukumaran
GANDHI, Manish Harendraprasad
Priority Data
202421006466
31.01.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3478 | |
| EPO | Filing, Examination, Granting | 23285 | |
| Japan | Filing, Examination, Granting | 2923 | |
| South Korea | Filing, Examination, Granting | 3370 | |
| USA | Filing, Examination, Granting | 12390 |
Total:
45,446
Abstract[English]
The invention relates to multimers containing (i) a plurality of target peptide (TP) sequences, each of which is a GLP-1 analogue or a fragment thereof, (ii) Cleavage site (CS) between the target peptide (TP) sequences, and (iii) optionally one or more Tag amino acid sequences that modulate pI and hydrophobicity. The multimers permit high levels of expression of target peptide (TP) sequences and have desired solubility for ease of downstream processing and purification.[French]
L'invention concerne des multimères contenant (i) une pluralité de séquences peptidiques cibles (TP), dont chacune est un analogue du GLP-1 ou un fragment de celui-ci, (ii) un site de clivage (CS) entre les séquences peptidiques cibles (TP), et (iii) éventuellement une ou plusieurs séquences d'acides aminés Tag qui modulent pI et l'hydrophobicité. Les multimères permettent des niveaux élevés d'expression de séquences peptidiques cibles (TP) et ont une solubilité souhaitée pour une facilité de traitement et de purification en aval.